FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and concerns using a pharmaceutical combination for treating liposarcoma. Pharmaceutical combination contains (i) (S)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, or a pharmaceutically acceptable salt thereof, and (ii) 7-cyclopentyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, or its pharmaceutically acceptable salt.
EFFECT: invention provides effective treatment of liposarcoma in a patient.
9 cl, 3 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MDM2 INHIBITORS AND COMBINATIONS THEREOF | 2016 |
|
RU2740091C2 |
| DISCONTINUOUS INTRODUCTION OF MDM2 INHIBITOR | 2015 |
|
RU2695228C2 |
| GDF-15 AS A HAEMATOLOGICAL TOXICITY BIOMARKER | 2016 |
|
RU2741390C2 |
| COMBINATION INCLUDING CYCLIN-DEPENDENT KINASE 4 INHIBITOR OR CYCLIN-DEPENDENT KINASE 6 INHIBITOR (CDK4/6) AND mTOR INHIBITOR FOR TREATING CANCER | 2011 |
|
RU2589696C2 |
| DOSE AND SCHEME OF INJECTION OF AN INHIBITOR OF INTERACTION OF HDM2 WITH p53 IN HEMATOLOGICAL TUMORS | 2018 |
|
RU2753527C2 |
| PHARMACEUTICAL COMBINATION CONTAINING ALK INHIBITOR AND SHP2 INHIBITOR | 2018 |
|
RU2769132C2 |
| PHARMACEUTICAL COMBINATIONS CONTAINING PYRIDO[4,3-d]PYRIMIDINE DERIVATIVES AS HSP90 INHIBITOR AND HER2 INHIBITOR | 2009 |
|
RU2532375C2 |
| DOSE AND INJECTION MODE FOR INHIBITORS OF INTERACTION OF HDM2 WITH P53 | 2017 |
|
RU2762573C2 |
| COMBINATIONS OF HSP90 INHIBITOR | 2009 |
|
RU2519673C2 |
| NEW CIS-IMIDAZOLINES | 2005 |
|
RU2408593C2 |
